Related Experiment Video

Updated: Apr 3, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

634

Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect

Pedro Sousa-Victor1,2, Laura García-Prat2, Pura Muñoz-Cánoves2

  • 1Buck Institute for Research on Aging, Novato, CA, USA.

Oncotarget
|September 17, 2015
PubMed

Insights

New non-rapamycin drugs targeting both mTORC1 and mTORC2 show promise in preventing cellular aging (geroconversion) more effectively than rapamycin, potentially offering future anti-aging therapies.

Area of Science:

  • Gerontology
  • Molecular Biology
  • Cellular Aging

Background:

  • Aging involves cellular and tissue decline, characterized by DNA damage, reactive oxygen species, and senescence.
  • Cellular aging, or geroconversion, involves a shift from reversible quiescence to irreversible senescence, halting proliferation.
  • The target of rapamycin (TOR) kinase pathway, particularly mTORC1, is implicated in promoting geroconversion.

Purpose of the Study:

  • To review recent advancements in targeting the TOR pathway for anti-aging interventions.
  • To highlight novel non-rapalog drugs that inhibit both mTORC1 and mTORC2.
  • To evaluate the potential of these new drugs in preventing cellular geroconversion.

Main Methods:

  • Discussion of recent research findings on non-rapalog drugs targeting mTORC1 and mTORC2.
  • Comparison of the efficacy of these novel drugs with rapamycin in preventing geroconversion.
  • Analysis of the impact on cellular senescence and proliferative potential.

Main Results:

  • Non-rapalog drugs targeting both mTORC1 and mTORC2 demonstrate enhanced prevention of geroconversion compared to rapamycin.
  • These novel drugs maintain cellular proliferative potential more effectively.
  • The simultaneous inhibition of both mTOR complexes offers a more potent anti-aging strategy.

Conclusions:

  • Novel non-rapalog drugs targeting mTORC1 and mTORC2 represent a promising therapeutic strategy against cellular aging.
  • These drugs could offer a more efficient approach to preventing age-related tissue dysfunction.
  • Further research into these compounds may lead to effective rejuvenating and anti-aging treatments.
Keywords:
aginggeroconversionmTORquiescencesenescence

More Related Videos

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.1K
Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.6K
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.4K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
323